Health News

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, Pharmacy, Tumor

Related posts

• ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco. Read [...]
  
  
• What Protein And Where It Is Located Are Important For Drug Design (0)
  Drugs that target a single signaling pathway that drives tumor development and/or progression have been developed successfully to treat a few forms of cancer. However, in many cases drugs designed using this approach have not worked. Dario Altieri and colleagues, at the University of Massachusetts Medical School, Worcester, have now addressed this issue by using [...]
  
  
• Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients (0)
  In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer. Read more [tags] Pharmacy News [/tags]
  
  
• TKM-PLK1 drug may offer hope for patients with advanced solid tumor cancers (0)
  A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare. Read more [tags] Pharmacy News [/tags]
  
  
• TGen licenses ONCO-101 cancer drug to Syracuse (0)
  The Translational Genomics Research Institute has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins. Read more [tags] Pharmacy News [/tags]